Veradermics

MANE · NYSE

$127.11+$4.83 (+3.95%)TodayMarket closed · Oct 20, 7:52 PM ET

Prev close $122.28

Latest news

NewsOct 19, 1:27 PM ETVandana Singh
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough
NewsOct 19, 10:05 AM ETAvi Kapoor
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
Press releaseOct 19, 7:00 AM ETBusiness Wire
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Press releaseOct 18, 6:00 PM ETBusiness Wire
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
NewsOct 8, 9:53 AM ETAvi Kapoor
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
Press releaseSep 3, 5:33 PM ETBusiness Wire
Veradermics to Present at Upcoming September Investor Conferences
Press releaseAug 11, 7:30 AM ETBusiness Wire
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Press releaseJul 17, 7:30 AM ETBusiness Wire
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
NewsJul 15, 1:47 PM ETVandana Singh
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
NewsJul 15, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsJul 15, 9:56 AM ETAvi Kapoor
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday
Press releaseJul 15, 7:00 AM ETBusiness Wire
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
Press releaseJul 14, 6:54 PM ETBusiness Wire
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Press releaseJun 2, 8:30 AM ETGlobe Newswire
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Press releaseMay 28, 4:30 PM ETBusiness Wire
Veradermics to Present at Upcoming June Investor Conferences
Press releaseMay 27, 7:30 AM ETBusiness Wire
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 '302' Study of VDPHL01 at the 2026 World Congress for Hair Research
Press releaseMay 14, 7:30 AM ETBusiness Wire
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Press releaseMay 12, 7:30 AM ETBusiness Wire
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Press releaseApr 29, 10:32 PM ETBusiness Wire
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
Press releaseApr 27, 5:26 PM ETBusiness Wire
Veradermics Announces Launch of Public Offering
NewsApr 27, 12:21 PM ETAvi Kapoor
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings
NewsApr 27, 11:13 AM ETVandana Singh
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
Press releaseApr 27, 7:00 AM ETBusiness Wire
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss
Press releaseApr 26, 4:00 PM ETBusiness Wire
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 '302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Press releaseMar 30, 7:30 AM ETBusiness Wire
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Press releaseMar 18, 7:00 AM ETBusiness Wire
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
Press releaseMar 3, 7:00 AM ETBusiness Wire
Veradermics to Participate in Upcoming March Investor Conferences
Press releaseFeb 12, 8:55 AM ETPRNewswire
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
Press releaseFeb 9, 7:30 AM ETBusiness Wire
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
Press releaseFeb 5, 4:05 PM ETBusiness Wire
Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
Press releaseFeb 4, 8:55 AM ETPRNewswire
NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA
Press releaseFeb 3, 9:57 PM ETBusiness Wire
Veradermics Announces Pricing of Upsized Initial Public Offering

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough

Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday

Veradermics to Present at Upcoming September Investor Conferences

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

12 Health Care Stocks Moving In Wednesday's Intraday Session

PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday

Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Veradermics to Present at Upcoming June Investor Conferences

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 '302' Study of VDPHL01 at the 2026 World Congress for Hair Research

Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics Announces Pricing of Upsized Public Offering and Private Placement

Veradermics Announces Launch of Public Offering

Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings

Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains

Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 '302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

Veradermics to Participate in Upcoming March Investor Conferences

NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA

Veradermics Announces Pricing of Upsized Initial Public Offering